ImmuneOnco Biopharmaceuticals

China clinical-stage biopharma, immuno-oncology + newer PAH program

1541 · HKEX · China

Public Market Listing

1541HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for ImmuneOnco Biopharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 2
PD-L1 / VEGFMultispecific antibody
Non-Small Cell Lung Cancer
Phase 1/2
Activin receptor type IIA (ActRIIA)Biologic (subtype unspecified)
Indication not yet linked

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
Palverafusp alfaPhase 2HCC - Hepatocellular Carcinoma
Est. primary completion 2027-07-23 · NCT07687914 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Palverafusp alfaPhase 1/2Advanced Solid Tumors
Est. primary completion 2029-02 · NCT07170787 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$5.3M$23M——report ↗

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$45M—$44Mreport ↗

ImmuneOnco Biopharmaceuticals reported R&D spend of $44.93M and a quarterly net burn of $43.97M for fiscal year 2024.

Figures only: this period's report disclosed no narrative text